141 related articles for article (PubMed ID: 30499053)
1. Short rare minisatellite variant of BORIS-MS2 is related to bladder cancer susceptibility.
Kim TN; Kim WT; Jeong MS; Mun MH; Kim MH; Lee JZ; Leem SH
Genes Genomics; 2019 Feb; 41(2):249-256. PubMed ID: 30499053
[TBL] [Abstract][Full Text] [Related]
2. A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.
Yoon SL; Roh YG; Chu IS; Heo J; Kim SI; Chang H; Kang TH; Chung JW; Koh SS; Larionov V; Leem SH
Exp Mol Med; 2016 Jul; 48(7):e246. PubMed ID: 27416782
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility for breast cancer in young patients with short rare minisatellite alleles of BORIS.
Yoon SL; Kim DC; Cho SH; Lee SY; Chu IS; Heo J; Leem SH
BMB Rep; 2010 Oct; 43(10):698-703. PubMed ID: 21034534
[TBL] [Abstract][Full Text] [Related]
4. Analysis of promoter methylation and polymorphic minisatellites of BORIS and lack of association with gastric cancer.
Yoon SL; Roh YG; Lee SH; Kim SH; Kim MC; Kim SJ; Leem SH
DNA Cell Biol; 2011 Sep; 30(9):691-8. PubMed ID: 21495859
[TBL] [Abstract][Full Text] [Related]
5. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
[TBL] [Abstract][Full Text] [Related]
7. Variants of MUC5B minisatellites and the susceptibility of bladder cancer.
Ahn EK; Kim WJ; Kwon JA; Choi PJ; Kim WJ; Sunwoo Y; Heo J; Leem SH
DNA Cell Biol; 2009 Apr; 28(4):169-76. PubMed ID: 19191526
[TBL] [Abstract][Full Text] [Related]
8. Short rare MUC6 minisatellites-5 alleles influence susceptibility to gastric carcinoma by regulating gene.
Kwon JA; Lee SY; Ahn EK; Seol SY; Kim MC; Kim SJ; Kim SI; Chu IS; Leem SH
Hum Mutat; 2010 Aug; 31(8):942-9. PubMed ID: 20506113
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Relationship between
Jeong MS; Mun JY; Yang GE; Kim MH; Lee SY; Choi YH; Kim HS; Nam JK; Kim TN; Leem SH
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254939
[No Abstract] [Full Text] [Related]
10. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
[TBL] [Abstract][Full Text] [Related]
11. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
[TBL] [Abstract][Full Text] [Related]
12. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
13. HRAS1 variable number of tandem repeats polymorphism and risk of bladder cancer.
van Gils CH; Conway K; Li Y; Taylor JA
Int J Cancer; 2002 Aug; 100(4):414-8. PubMed ID: 12115522
[TBL] [Abstract][Full Text] [Related]
14. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
[TBL] [Abstract][Full Text] [Related]
15. BORIS in human cancers -- a review.
Martin-Kleiner I
Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
[TBL] [Abstract][Full Text] [Related]
16. The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.
Pugacheva EM; Teplyakov E; Wu Q; Li J; Chen C; Meng C; Liu J; Robinson S; Loukinov D; Boukaba A; Hutchins AP; Lobanenkov V; Strunnikov A
Epigenetics Chromatin; 2016; 9(1):35. PubMed ID: 27588042
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
[TBL] [Abstract][Full Text] [Related]
18. Widespread expression of BORIS/CTCFL in normal and cancer cells.
Jones TA; Ogunkolade BW; Szary J; Aarum J; Mumin MA; Patel S; Pieri CA; Sheer D
PLoS One; 2011; 6(7):e22399. PubMed ID: 21811597
[TBL] [Abstract][Full Text] [Related]
19. A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer.
Wang S; Wang M; Yin S; Fu G; Li C; Chen R; Li A; Zhou J; Zhang Z; Liu Q
Mutat Res; 2008 Feb; 638(1-2):26-36. PubMed ID: 17904587
[TBL] [Abstract][Full Text] [Related]
20. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.
D'Arcy V; Pore N; Docquier F; Abdullaev ZK; Chernukhin I; Kita GX; Rai S; Smart M; Farrar D; Pack S; Lobanenkov V; Klenova E
Br J Cancer; 2008 Feb; 98(3):571-9. PubMed ID: 18195709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
